Focused On-demand Library for U8 snoRNA-decapping enzyme

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

IDP phosphatase; Inosine diphosphate phosphatase; Nucleoside diphosphate-linked moiety X motif 16; Nudix hydrolase 16; U8 snoRNA-binding protein H29K; m7GpppN-mRNA hydrolase

Alternative UPACC:

Q96DE0; B4E3B4; E9PED4; F5GYJ1; Q96N82


The U8 snoRNA-decapping enzyme, also known as Nudix hydrolase 16, plays a crucial role in RNA metabolism. It catalyzes the cleavage of cap structures of snoRNAs and mRNAs, essential for the maturation of rRNA and mRNA degradation. This enzyme exhibits specificity for various RNA species, acting in a metal-dependent manner, and binds to U8 snoRNA without requiring metal for RNA-binding. Its activity extends to hydrolyzing non-canonical purine nucleotides, thus maintaining nucleotide pool integrity and preventing chromosomal lesions.

Therapeutic significance:

Understanding the role of U8 snoRNA-decapping enzyme could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.